ArticleDiabetes2025
Association Between Myristic Acid in Plasma Triglycerides and Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Comprehensive Analysis of Plasma Lipids Using Supercritical Fluid Chromatography-Tandem Mass Spectrometry.
Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of the Gut-Liver-Kidney Axis in Disease Manifestation and Biomarker Alterations.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This study aimed to investigate the relationship between the plasma lipidome and metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes. Initially, we conducted a plasma lipidome analysis using supercritical fluid chromatography-tandem mass spectrometry in 143 patients with type 2 diabetes with and without MASLD. Of the 349 lipid species identified, 13 had higher levels and a fold-change ≥2 in the MASLD group than in the non-MASLD group; 10 of these 13 lipids were triglycerides (TGs). The constituent fatty acid (FA) in TGs that exhibited the greatest difference between patients with and without MASLD was myristic acid (FA 14:0). The presence of MASLD was an independent explanatory factor for high FA 14:0 levels in TGs, even after adjusting for covariates. Next, we assessed whether the levels of lipids identified in the initial analysis were influenced by comprehensive diabetes treatment in 26 patients. After comprehensive diabetes treatment of 2 weeks, FA levels in many TGs significantly decreased; especially FA 14:0 levels, and this reduction was more pronounced in patients with MASLD. These results suggest that various plasma lipids, particularly TGs comprising FA 14:0, may be associated with the pathogenesis of MASLD in patients with type 2 diabetes. ARTICLE HIGHLIGHTS: Changes in blood lipid profiles in type 2 diabetes, particularly when complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), have not been fully elucidated. Does MASLD influence the plasma lipidome in patients with type 2 diabetes? Patients with MASLD exhibited elevated levels of myristic acid (FA 14:0) in plasma triglycerides, which significantly decreased after comprehensive diabetes treatment. Elevated FA 14:0 levels in triglycerides may be associated with MASLD pathogenesis in type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.